|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EBLN3P |
Gene summary for EBLN3P |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EBLN3P | Gene ID | 100506710 |
| Gene name | endogenous Bornavirus like nucleoprotein 3, pseudogene | |
| Gene Alias | EBLN3 | |
| Cytomap | 9p13.2 | |
| Gene Type | pseudo | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100506710 | EBLN3P | GSM4909281 | Human | Breast | IDC | 2.49e-04 | 2.46e-01 | 0.21 |
| 100506710 | EBLN3P | GSM4909285 | Human | Breast | IDC | 2.00e-23 | 4.64e-01 | 0.21 |
| 100506710 | EBLN3P | GSM4909286 | Human | Breast | IDC | 2.61e-03 | 1.43e-01 | 0.1081 |
| 100506710 | EBLN3P | GSM4909290 | Human | Breast | IDC | 2.79e-14 | 4.80e-01 | 0.2096 |
| 100506710 | EBLN3P | GSM4909292 | Human | Breast | IDC | 8.99e-09 | 8.21e-01 | 0.1236 |
| 100506710 | EBLN3P | GSM4909293 | Human | Breast | IDC | 6.93e-10 | 2.70e-01 | 0.1581 |
| 100506710 | EBLN3P | GSM4909298 | Human | Breast | IDC | 2.22e-11 | 3.38e-01 | 0.1551 |
| 100506710 | EBLN3P | GSM4909304 | Human | Breast | IDC | 1.41e-19 | 4.57e-01 | 0.1636 |
| 100506710 | EBLN3P | GSM4909307 | Human | Breast | IDC | 4.28e-02 | 2.32e-01 | 0.1569 |
| 100506710 | EBLN3P | GSM4909308 | Human | Breast | IDC | 1.10e-10 | 3.54e-01 | 0.158 |
| 100506710 | EBLN3P | GSM4909311 | Human | Breast | IDC | 5.31e-03 | -1.34e-02 | 0.1534 |
| 100506710 | EBLN3P | GSM4909317 | Human | Breast | IDC | 1.58e-04 | 2.23e-01 | 0.1355 |
| 100506710 | EBLN3P | GSM4909319 | Human | Breast | IDC | 2.37e-05 | -3.25e-02 | 0.1563 |
| 100506710 | EBLN3P | brca1 | Human | Breast | Precancer | 7.01e-03 | -1.28e-01 | -0.0338 |
| 100506710 | EBLN3P | brca2 | Human | Breast | Precancer | 1.57e-03 | -1.28e-01 | -0.024 |
| 100506710 | EBLN3P | brca3 | Human | Breast | Precancer | 7.01e-03 | -1.28e-01 | -0.0263 |
| 100506710 | EBLN3P | M5 | Human | Breast | IDC | 1.13e-02 | 5.50e-01 | 0.1598 |
| 100506710 | EBLN3P | DCIS2 | Human | Breast | DCIS | 1.43e-43 | 2.27e-01 | 0.0085 |
| 100506710 | EBLN3P | NAFLD1 | Human | Liver | NAFLD | 1.56e-05 | 4.49e-01 | -0.04 |
| 100506710 | EBLN3P | HCC2 | Human | Liver | HCC | 1.37e-10 | 3.19e+00 | 0.5341 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |